US Capitol Capsule: Will Myriad BRCA case relieve biopharma's patent anxiety?
This article was originally published in Scrip
Executive Summary
Dumbfounded by the US Supreme Court's 20 March decision invalidating diagnostic methods patents held by Prometheus Laboratories, the biopharma industry is bracing for the next court battle about what is or isn't patentable subject matter when the US Court of Appeals for the Federal Circuit hears oral arguments on 20 July on whether Myriad Genetics' composition patent claims covering the BRCA1 and BRCA2 genes are valid.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.